GlycoMimetics to Present at Four Investor Conferences This Month

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March, including:

30th Annual ROTH ConferenceMarch 11 – 14, 2018, The Ritz Carlton, Dana Point, CACFO Brian Hahn will present on March 12 at 3:30 p.m. PT.

Cowen 38th Annual Health Care ConferenceMarch 11 – 14, 2018, Copley Place Marriott, Boston, MACEO Rachel King will present on March 14 at 9:20 a.m. ET.

BioCentury: 25th Annual Future Leaders in the BioTech IndustryMarch 23, 2018, Millennium Broadway Hotel & Conference Center, New York, NYMrs. King will present in room 311 at 2:30 p.m. ET.

Needham & Company’s 17th Annual HealthCare ConferenceMarch 27 – 28, 2018, Westin Grand Central Hotel, New York, NYMrs. King will present on March 27 at 8:00 a.m. ET.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180307005331/en/

For GlycoMimetics, Inc.
Investors:
Shari Annes, 650-888-0902
[email protected]
or
Media:
Jamie Lacey-Moreira, 410-299-3310
[email protected]

Source: GlycoMimetics, Inc.

You May Also Be Interested In

• Needham Starts Faeth Therapeutics (FTH) at Buy
• Dr. Ahlem Arfaoui Recognized with the Best Author on Election Law and Reform in New York of 2026 Award, Announces Release of The Power of the Political Contribution in the United States, a New Analysi
• TalkGraph Announces AI Platform Designed to Turn Conversation Into a Living Second Brain